![Salim Dhanji](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 10 M $ in data 31/08/2026
Salim Zulifkar Dhanji is President, Chief Executive Officer & Director at ME Therapeutics Holdings, Inc. since 2023.
Dr. Dhanji is President at Perceptive Property Development since 2013.
Formerly, Dr. Dhanji was Director-Preclinical Research at Qu Biologics, Inc. from 2009 to 2014.
Education includes an undergraduate degree (2001) and a doctorate (2006) from the University of British Columbia.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 16/07/2026 | 4.175.143 ( 13,89% ) | 10 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Amministratore Delegato | 09/03/2023 |
| Società | Posizione | Fine |
|---|---|---|
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer | Corporate Officer/Principal | 01/01/2014 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 3 |
|---|---|
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer | Health Technology |
ME Therapeutics Holdings, Inc.
 ME Therapeutics Holdings, Inc. BiotechnologyHealth Technology Provides biotechnology and pharmaceutical services | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
